Month: February 2024

On February 23, 2024, the biopharmaceutical plant of OtarBioPharm LLP was visited by students and teachers of the Kazakh National Medical University named after S.D. Asfendiyarov under the guidance of associate professor, Candidate of Biological Sciences Suleimenov Marat Kamytbekovich. The purpose of the visit is a personal acquaintance with the domestic pharmaceutical industry.

 

According to the program of the visit, accompanied by A.K. Satybaldiyev, Deputy General Director of OtarBioPharm LLP, the visitors got acquainted with the entire production line, quality control laboratories and mandatory auxiliary systems and equipment, such as water treatment system, inspection equipment, labeling equipment, dispatch system, etc.

As befits young people, students were interested in everything – “What is the vaccine made of?”, “Did the President really visit the plant?”, “What is GMP?”, “What is quality control?” etc.

In addition, the students got acquainted with the workers who produced the QazVac vaccine, a domestic vaccine against Covid-19 coronavirus infection.

In conclusion we can say that what students saw exceeded their expectations about the domestic plant for the production of immunobiological drugs.

On February 13, 2024, the representatives of the international pharmaceutical company «The Say Pharma», accompanied by the head of the International Cooperation Department of JSC «National Holding «QazBioPharm» Abit Bekjigit Begmatullauli visited the Biopharmaplant.

General Director Zakir Yershebulov held a presentation of the plant.

Next, the guests examined the water treatment unit and the production line

After an introductory review, representatives of «National Holding «QazBioPharm», «OtarBioPharm» and The Say Pharma» held talks on the possibility of cooperation.

Director of «The SaaPharma» LLP, representative office of «The Say Pharma» company in the Republic of Kazakhstan Nazgul Orazkhanova listed the portfolio of biologics, equipment, etc. supplied by her company. According to representatives of The Say Pharma, the visit was of an introductory nature and, at the discretion of the company, a visit of representatives in senior positions should take place.

At the end of the negotiations, the parties were hopeful of further cooperation.